Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

555 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To compare patient-led titration (intervention group) versus physician-led titration (usual standard of care) in optimizing the clinical use of insulin glargine in an Asian population of patients with Type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetic drugs (OADs).

Secondary Objectives:

To determine the difference in glycemic control, safety, quality of life and treatment satisfaction between patient-led titration and usual care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control

NCT00701831

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study

NCT00539448

Diabetes Mellitus, Type 1

COMPLETED PHASE4

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082

Diabetes Mellitus, Type 1

COMPLETED PHASE3

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)

NCT00390728

Diabetes Mellitus, Type 1

COMPLETED PHASE4

Lantus Versus Levemir Treat-To-Target

NCT00405418

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days

Group Type EXPERIMENTAL

Insulin Glargine

Intervention Type DRUG

Pharmaceutical form: solution for injection

Route of administration: subcutaneous

Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target

Usual standard of care group

Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician

Group Type ACTIVE_COMPARATOR

Insulin Glargine

Intervention Type DRUG

Pharmaceutical form: solution for injection

Route of administration: subcutaneous

Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin Glargine

Pharmaceutical form: solution for injection

Route of administration: subcutaneous

Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Solostar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with T2DM duration of T2DM \> 2 years
2. Insulin naïve
3. Continuous treatment with stable doses of 2 OADs (sulphonylureas, biguanides, alpha-glucosidase inhibitors, DPP-IV inhibitors, and glinides) for \> three months prior to randomization
4. HbA1c levels 7% and 11 %
5. Body mass index (BMI) 20 and 40 kg/m2
6. Willing and able to perform blood glucose monitoring using a blood glucose meter

Exclusion Criteria

1. Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agent intake),
2. Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for \< 1 week),
3. Current treatment with thiazolidinediones,
4. Current or previous use (within the last 3 months) of GLP-1 receptor agonists or GLP-1 analogues,
5. Current or previous (within the last 3 months) use of any treatment for weight lost,
6. Active proliferative diabetic retinopathy,
7. Patient without any history of eye examination in the past 6 months,
8. Treatment with systemic corticosteroids in the 3 months prior to study entry,
9. Currently receiving treatment with monoamine oxidase inhibitors,
10. Currently receiving treatment with non-selective -blockers,
11. Treatment with any investigational product and/or device in the 2 months prior to study entry,
12. Likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol,
13. History of ketoacidosis or hyperosmolar hyperglycemic state,
14. History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months,
15. History of congestive heart failure,
16. History of hypoglycemia unawareness,
17. Unexplained hypoglycemia in the past 6 months,
18. Impaired renal function defined as, but not limited to, serum creatinine 1.5 mg/dL (133 mol/L) males or 1.4 mg/dL (124 mol/L) females or presence of macroproteinuria (\>2gr/day),
19. Active liver disease (alanine transaminase ALAT greater than two times the upper limit of the reference range, as defined by the local laboratory),
20. Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol,
21. Had a blood transfusion or severe blood loss within the 3 months before screening, or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia,
22. Known hypersensitivity / intolerance to insulin glargine or any of its excipients,
23. History of pancreatitis,
24. Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma),
25. Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),
26. Any medical condition that may have an influence on HbA1c rate.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No